Navigation Links
Concerns Regarding Overstenting Will Limit the US Market for Interventional Cardiology Devices Through 2022
Date:12/11/2013

TORONTO, Dec. 11, 2013 /PRNewswire/ -- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, the United States market for interventional cardiology (IC) devices will be hindered by ongoing concerns over overstenting and the appropriate use of percutaneous coronary intervention (PCI). As a result, PCI volumes will continue to decline through 2018 before stabilizing. However, total IC device revenues will continue to fall through 2022 due to cost sensitivity and healthcare reforms.

(Logo:  http://photos.prnewswire.com/prnh/20130103/MM36799LOGO )

In this declining market, technological innovation will offer the best opportunity for companies to gain revenues. This has been most evident within the coronary stent segment. Abbott is expected to gain approval for the first bioresorbable vascular scaffold (BVS), ABSORB, in 2017; ABSORB received CE marking in Europe in 2011, and there is already significant interest in this device among US physicians. This product features a scaffold made of a polymer that completely dissolves in the vasculature over time, allowing the vessel to heal and return to normal. BVS are expected to offer clinical results similar to drug-eluting stents (DES), while supporting an improved safety profile. Although this product will initially be priced at a premium and will face significant competition from DES, ABSORB represents a major innovation and is likely to capture share within the coronary stent segment.

"A number of other stent technologies are expected to enter the market through 2022, many from smaller competitors focusing on niche segments," said MRG Senior Analyst Ian Swanson. "For example, Tryton Medical's TRYTON is a dedicated bifurcation stent, currently in clinical trials. InspireMD is developing a stent specifically designed to treat ST-segment elevation myocardial infarction patients. Similarly, STENTYS' product will be a self-apposing, self-expanding stent designed to treat patients suffering from acute myocardial infarction. Each of these devices is aimed at a specific difficult-to-treat patient niche and seeks to offer improved treatment options over currently available devices."

Millennium Research Group's US Markets for Interventional Cardiology Devices 2014 report includes procedure, unit, average selling price and revenue information, along with market drivers and limiters and a competitive landscape for coronary stents, percutaneous transluminal coronary angioplasty balloon catheters, accessory devices, intravascular imaging and pressure guidewires and coronary atherectomy devices in the United States.

About Millennium Research Group
Millennium Research Group (www.MRG.net), a Decision Resources Group company (www.DecisionResourcesGroup.com), is the global authority on medical technology market intelligence and the leading provider of strategic information to the healthcare sector. The company provides specialized industry expertise through multiclient market research, ongoing Marketrack™ projects, customer loyalty tracking, facility-level procedure forecasting, and customized solutions.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:



Christopher Comfort
Decision Resources Group
781-993-2597
ccomfort@dresources.com

Alex Jablokow
Millennium Research Group
617-599-8613
ajablokow@mrg.net

 


'/>"/>
SOURCE Millennium Research Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Obesity Therapeutics to 2019 - Safety Concerns Hinder Drug Performance Despite Large Market Opportunity
2. ResearchMoz.us: Obesity Therapeutics to 2019 - Safety Concerns Hinder Drug Performance Despite Large Market Opportunity
3. Obama administrations Plan B Decision Ignores Safety, Parental Rights Concerns
4. Green Valley Drugs Announces Voluntary Nationwide Recall Of All Lots Of All Sterile Products Compounded, Repackaged, And Distributed By Green Valley Drugs Due To Quality Control Concerns
5. Contraceptives Market to 2018 - Safety Concerns Plague Drospirenone-containing Birth Control Pills and Long-term Use of Estrogen
6. DePuy Settlement News In Bellwether Case Concerns Plaintiffs Of The Hip Recall
7. New White Paper, "Five Biggest Myths about Medical Products Outsourcing," Finds OEMs Concerns are Often Unfounded
8. New Study Answers CMS/USPSTF Concerns for CT Colonography Screening Reimbursement: It is a Viable Option for the Medicare-Aged Population
9. Frost & Sullivan to Host Complimentary Web Conference: Concerns and Solutions for the Anaesthesia Equipment and Associated Peripherals Market
10. Ambit Biosciences Provides Regulatory Update Following FDA Meeting Regarding Quizartinib (AC220)
11. Panacea Pharmaceuticals Presents Three Papers Regarding Its Nanoparticle-Based Therapeutic Cancer Vaccine at the Society for Immunotherapy of Cancer Annual Meeting at National Harbor, MD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... Dec. 6, 2016  BioAtla, LLC, a ... of Conditionally Active Biologic (CAB) antibody therapeutics, ... Group Company, Limited (Sinobioway) selected their first ... specific program candidates and the targeted indications ... and Sinobioway entered into a strategic collaboration ...
(Date:12/6/2016)... HASTINGS ON HUDSON, N.Y. , Dec. 6, ... anxiety, there,s now a reason to be hopeful. ... the way to a less anxious life. ... Robert Buck, the psychotherapist ... they represent a breakthrough approach to overcoming anxiety ...
(Date:12/5/2016)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) ... previously-announced cash tender offers (the "Offers") for the ... the "Notes"), approximately $2.6 billion in aggregate principal amount ... withdrawn on or prior to 5:00 p.m., ... 5, 2016 (the "Early Tender Deadline"). The Company ...
Breaking Medicine Technology:
(Date:12/6/2016)... (PRWEB) , ... December 06, 2016 , ... ... the impact of new federal healthcare regulations at the 7th annual Health IT ... Atlanta. , Andy Slavitt, acting administrator for the Centers for Medicare & Medicaid ...
(Date:12/6/2016)... ... December 06, 2016 , ... Gateway Analytical, ... offering HIAC particle counting and sizing services for USP 788 and 789 particulate ... new service as a response to the needs of pharmaceutical and medical device ...
(Date:12/6/2016)... ... 2016 , ... 'Tis the season for family, festivity, food and fun! Temptation ... season when eating healthy, staying active, and taking medication and doing daily foot health ... , "Shopping trips, parties and family gatherings can take their toll on our ...
(Date:12/6/2016)... ... December 06, 2016 , ... The OSHA ... Training Institute Education Center headquartered in Northern California, has announced the addition of ... safety and health training to public sector employees. , “The primary goal of ...
(Date:12/5/2016)... ... December 05, 2016 , ... Edward Buckingham MD , ... arrival of the newest Sciton laser in January 2017. The Halo is the ... and ablative wavelengths for exceptional results. Outperforming more traditional lasers, the innovative Halo ...
Breaking Medicine News(10 mins):